116 related articles for article (PubMed ID: 3193964)
1. Dementia and treatment with L-dopa in Parkinson's disease.
Hietanen M; Teräväinen H
Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of early dopa treatment in Parkinson's disease.
Markham CH; Diamond SG
Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
[TBL] [Abstract][Full Text] [Related]
3. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Hely MA; Morris JG; Reid WG; Trafficante R
Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
Lange KW; Paul GM; Naumann M; Gsell W
J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
[TBL] [Abstract][Full Text] [Related]
6. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.
Schrag A; Ben-Shlomo Y; Brown R; Marsden CD; Quinn N
Mov Disord; 1998 Nov; 13(6):885-94. PubMed ID: 9827611
[TBL] [Abstract][Full Text] [Related]
7. Early-onset Parkinson's disease.
Giovannini P; Piccolo I; Genitrini S; Soliveri P; Girotti F; Geminiani G; Scigliano G; Caraceni T
Mov Disord; 1991; 6(1):36-42. PubMed ID: 2005920
[TBL] [Abstract][Full Text] [Related]
8. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
9. Single-dose L-dopa response in early Parkinson's disease: measurements with optoelectronic recording technique.
Johnels B; Ingvarsson PE; Holmberg B; Matousek M; Steg G
Mov Disord; 1993; 8(1):56-62. PubMed ID: 8419808
[TBL] [Abstract][Full Text] [Related]
10. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
[TBL] [Abstract][Full Text] [Related]
11. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
Shif M; Kempster PA
Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
[TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
14. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
15. Deep brain stimulation of the subthalamic nucleus and cognitive functions in Parkinson's disease.
Klempírová O; Jech R; Urgosík D; Klempír J; Spacková N; Roth J; Růzicka E
Prague Med Rep; 2007; 108(4):315-23. PubMed ID: 18780643
[TBL] [Abstract][Full Text] [Related]
16. Young onset Parkinson's disease.
Quinn N; Critchley P; Marsden CD
Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
[TBL] [Abstract][Full Text] [Related]
17. Clinical observations in early and late onset Parkinson's disease.
Bostantjopoulou S; Logothetis J; Katsarou Z; Mentenopoulos G
Funct Neurol; 1991; 6(2):145-9. PubMed ID: 1916456
[TBL] [Abstract][Full Text] [Related]
18. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
Bouhaddi M; Vuillier F; Fortrat JO; Cappelle S; Henriet MT; Rumbach L; Regnard J
Auton Neurosci; 2004 Nov; 116(1-2):30-8. PubMed ID: 15556835
[TBL] [Abstract][Full Text] [Related]
19. [The effects of dopamine on regional cerebral blood flow in patients with Parkinson's disease before and after L-dopa--measurement by Xe-enhanced CT].
Aiba I; Indo T; Takahashi A
Rinsho Shinkeigaku; 1994 Nov; 34(11):1099-104. PubMed ID: 7729088
[TBL] [Abstract][Full Text] [Related]
20. Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy.
Marini P; Ramat S; Ginestroni A; Paganini M
Neurol Sci; 2003 Oct; 24(3):184-5. PubMed ID: 14598078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
